The company operates an integrated chlor-alkali plant producing caustic soda and chlorine, while also manufacturing high-performance Oriented PVC (OPVC) pipes for government-led water infrastructure projects.
The company possesses a narrow moat in its chemical division due to backward integration into captive salt fields and a cost-efficient integrated value chain. However, the commodity nature of caustic soda and the tender-driven, cyclical dependency of the OPVC pipe business on government funding are reflected in volatile and relatively low average ROCE (8.9%).
Management has aggressively reinvested in capacity expansion for OPVC pipes (growing from 3,000 TPA to 23,000 TPA) and technology upgrades in the chemical plant. While these are strategic, the financial results show a lag in returns, with ROE averaging only 5.4% despite significant capital outlay.
The aggressive expansion into OPVC pipes proved to be a classic capital-allocation trap, where massive reinvestment met a cyclical downturn in government infrastructure spending. As the Jal Jeevan Mission funding dried up, the company was left with 23,000 TPA of capacity and a heavy debt load that the low-margin caustic soda business could not service. The interest coverage ratio, already at a precarious 1.0, collapsed into negative territory, leading to a liquidity crunch and permanent impairment of shareholder equity as the business failed to earn its cost of capital.
RichFakir rates Chemfab Alkalis Ltd's business quality as poor — 25/100 on our quality score (profitability, growth, balance-sheet strength and capital allocation). We assess its competitive moat as narrow.
On our model, Chemfab Alkalis Ltd is trading about 7% below our estimate of fair value; we rate its price fair. This is an educational estimate from public filings, not a recommendation.
RichFakir's educational verdict on Chemfab Alkalis Ltd is: Not rated. A poor business at a fair price — it does not make our shortlist right now.
RichFakir's educational estimate of Chemfab Alkalis Ltd's fair value is about ₹313 per share, derived from public filings. It's our estimate for research — not a price target or a recommendation to buy or sell.
View the full live analysis →